SecBot SecBot
Biotech Drug Report Generated Oct 25, 2026

EMPAVELI

BIIB·Biogen Inc.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already approved and commercialized since May 2021. No pending approval for this drug in its current indication.
Why 3/10
Empaveli is already approved and commercialized (FDA approved May 2021) with no pending PDUFA or pivotal readout in the next ~12 months. It is one product within Biogen's large, diversified portfolio (~$10.4B annual revenue). Per the rubric, an approved drug with no pending regulatory decision and no dated binary catalyst scores 3-5; given its small weighting in Biogen's overall revenue mix, the low end of that range (3) is appropriate.
Actionable Insight NEUTRAL

Empaveli is now a mature asset inside Biogen's (BIIB) portfolio following the May 2026 Apellis acquisition. There is no imminent PDUFA or pivotal readout for this drug. Investors should focus on Biogen's quarterly PNH franchise revenue (Empaveli + pipeline) and the SYFOVRE sales trajectory (which drives CVR payouts for former Apellis shareholders) rather than expecting a binary stock-moving event from Empaveli specifically.

Price Chart

Loading chart...

Executive Summary

Empaveli (pegcetacoplan) is a complement C3 inhibitor approved by the FDA in May 2021 for paroxysmal nocturnal hemoglobinuria (PNH). Originally developed by Apellis Pharmaceuticals, the drug is now owned by Biogen (BIIB) following Biogen's ~$5.3B acquisition of Apellis in May 2026. Empaveli competes with Alexion/AstraZeneca's Soliris and Ultomiris in the PNH market. The same molecule is also marketed as SYFOVRE for geographic atrophy. As a mature, approved product within Biogen's large portfolio, Empaveli is not a near-term binary catalyst for BIIB stock, though its commercial performance contributes to Biogen's post-acquisition revenue diversification.

How It Works

Empaveli is a complement C3 inhibitor, it blocks a protein called C3 that is part of the body's immune complement system. In PNH, the immune system attacks red blood cells, causing their destruction (hemolysis). By blocking complement activity at an earlier stage than older drugs, Empaveli prevents red blood cell destruction more broadly. It is given as a subcutaneous (under the skin) injection.

Trial Status

Empaveli was approved by the FDA in May 2021 for paroxysmal nocturnal hemoglobinuria (PNH) under NDA215014. A Phase 3 long-term safety extension study in PNH (NCT03531255) completed in 2026. A Phase 2 trial in post-transplant recurrence of C3G/IC-MPGN (NCT04572854) completed with results. A Phase 3 extension study in geographic atrophy secondary to AMD (NCT04770545) also completed in 2025. In August 2026, FDA added a boxed warning for serious encapsulated bacterial infections.

The Two-Sided Case

▲ Bull Case3
Empaveli is a first-in-class C3 inhibitor that blocks the complement cascade upstream of C5, offering a differentiated mechanism vs. Soliris/Ultomiris that may capture patients with suboptimal response to C5 inhibitors.
The drug contributes to Biogen's post-acquisition revenue diversification beyond its core neurology franchise (MS, Spinraza, Leqembi), adding a complement-mediated hematology/ophthalmology platform.
Biogen's commercial infrastructure and global reach could expand Empaveli's market penetration beyond what Apellis could achieve alone. BIIB analyst consensus skews buy (29 buy/strongBuy out of 43 analysts).
▼ Bear Case4
Empaveli faces entrenched competition from Alexion/AstraZeneca's Soliris (eculizumab) and Ultomiris (ravulizumab), which are well-established C5 inhibitors with strong PNH market share and long safety track records.
The August 2026 FDA safety labeling update added a boxed warning for serious/fatal encapsulated bacterial infections, which could dampen prescriber confidence and patient uptake.
As a single product within Biogen's large portfolio (FY2026 consensus revenue ~$10.4B), Empaveli has limited ability to move BIIB's stock price meaningfully.
The $41/share acquisition price removed the upside leverage that APLS standalone shareholders once had; Empaveli/SYFOVRE performance now primarily matters for CVR milestone payouts rather than equity appreciation.

Upcoming Catalysts

  • No imminent PDUFA or pivotal readout for Empaveli as it is already approved and commercialized.
  • Quarterly Biogen earnings reports will disclose combined PNH franchise performance including Empaveli.
  • SYFOVRE (same molecule, intravitreal) sales milestones determine CVR payouts for former Apellis shareholders.
  • Potential label expansion for Empaveli into new complement-mediated indications remains a long-term pipeline opportunity.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Biogen Inc. Press Release BIIB ·Originating report

Sources · 3

Hover a chip for the title
1 sec.gov2 sec.gov3 sec.gov